Table 1.
Demographic and Baseline Characteristics
| Treatment Sequence | |||||||
|---|---|---|---|---|---|---|---|
| Variable | Sequence 1 (n = 8) | Sequence 2 (n = 8) | Sequence 3 (n = 8) | Sequence 4 (n = 8) | Sequence 5 (n = 8) | Sequence 6 (n = 8) | All Subjects (n = 48) |
| Age (years), mean (SD) | |||||||
| 28.0 (3.9) | 23.6 (3.4) | 26.6 (5.1) | 27.5 (5.7) | 27.6 (6.1) | 26.8 (4.7) | 26.7 (4.9) | |
| Sex, n (%) | |||||||
| Male | 6 (75.0) | 4 (50.0) | 5 (62.5) | 4 (50.0) | 4 (50.0) | 5 (62.5) | 28 (58.3) |
| Race, n (%) | |||||||
| White | 6 (75.0) | 2 (25.0) | 3 (37.5) | 3 (37.5) | 4 (50.0) | 4 (50.0) | 22 (45.8) |
| Black or African American | 2 (25.0) | 5 (62.5) | 5 (62.3) | 5 (62.5) | 4 (50.0) | 4 (50.0) | 25 (52.1) |
| American Indian or Alaska Native | 0 | 1 (12.5) | 0 | 0 | 0 | 0 | 1 (12.5) |
| Weighta (kg), mean (SD) | |||||||
| 82.7 (12.8) | 67.1 (11.2) | 66.9 (12.8) | 71.3 (7.2) | 65.9 (11.8) | 70.7 (12.4) | 70.7 (12.3) | |
| BMI (kg/m2), mean (SD) | |||||||
| 26.7 (2.6) | 22.8 (4.2) | 23.2 (2.9) | 25.3 (2.4) | 23.1 (3.3) | 24.0 (3.2) | 24.2 (3.3) | |
BMI, body mass index; B‐OLZ, brand olanzapine; OLZ, olanzapine; SD, standard deviation.
Treatment sequence 1 = ABC; 2 = BCA; 3 = CAB; 4 = ACB; 5 = BAC; 6 = CBA; where treatments A, B, C are OLZ, ALKS 3831, and B‐OLZ, respectively.
a
Weight measured at baseline, which is defined as the day −1 assessment in period 1 (or the last nonmissing value before the first dose if the day −1 assessment in period 1 was missing).